With competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes will keep its Nucala drug ahead of its rivals. The European Commission has approved ...

GlaxoSmithKline Pharmaceuticals Limited is ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India. It launched Trelegy Ellipta, the countrys first single inhaler ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as ... the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...